沙格列汀联合二甲双胍治疗T2DM代谢性肥胖患者对其体脂成分的改善效果  

Improvement Effect of Saxagliptin and Metformin on the Body Fat Composition in Patients with T2DM Metabolic Fat

作　　者：夏镇萍 XIA Zhenping(First People's Hospital of Zhenjiang,Jiangsu Province,Zhenjiang 212002,China)

机构地区：[1]江苏省镇江市第一人民医院,江苏镇江212002

出　　处：《中国医药指南》2021年第26期97-98,共2页Guide of China Medicine

摘　　要：目的分析沙格列汀联合二甲双胍治疗2型糖尿病(T2DM)代谢性肥胖患者对其体脂成分的改善效果。方法选择我院2018年1月至2019年9月收治的门诊就诊的90例T2DM代谢性肥胖患者为观察对象,通过随机数字分配原则将其分为两组,即为对照组(n=45)与观察组(n=45),对照组患者应用胰岛素治疗,观察组患者在胰岛素治疗基础上给予沙格列汀联合二甲双胍治疗,比较两组干预后对患者体脂成分的改善情况。结果干预后,观察组FBG、2 hPG及HbA_(1)c水平低于对照组,差异有统计学意义(P<0.05);两组TC、TG、LDL-C及HDL-C水平与治疗前比较,差异无统计学意义(P>0.05)。观察组患者治疗后SBP、DBP血压水平低于对照组,WC水平稍低于对照组,组间差异有统计学意义(P<0.05)。结论对T2DM代谢性肥胖患者应用沙格列汀联合二甲双胍治疗,可显著改善其腰围与血压水平。Objective To analyze the improvement effect of sagliptin and metformin in patients with type 2 diabetes(T2DM).Methods The 90 patients with T2DM metabolic obesity in September 2018 since January 2018 were selected as observation by digital randomized distribution,control group(n=45)and(n=45),who used insulin treatment and treated saxagliptin and metformin based on insulin therapy to comparing the improvement of body fat composition after intervention.Results The FBG,2 hPG and HbA_(1)c levels were lower than the controls(P<0.05);TC,TG,LDL-C and HDL-C levels were not before treatment(P>0.05).Moreover,the SBP,DBP blood pressure level was lower than the control group and slightly lower than the control group,with statistically significant data differences between the two groups(P<0.05).Conclusion The treatment of saxagliptin and metformin in T2DM metabolic obesity patients can significantly improve the waist circumference and blood pressure level and is widely used in clinic.

关 键 词：2型糖尿病 沙格列汀 二甲双胍 代谢性肥胖 体脂成分 

分 类 号：R5871[医药卫生—内分泌]